The purpose of the study was to examine the indicators of carbohydrate, energy and adipokine metabolism in acute myocardial infarction patients with or without type 2 diabetes mellitus. Materials and methods. A total of 134 patients with ST-segment elevation acute myocardial infarction in the presence or absence of type 2 diabetes mellitus aged 58.97 ± 7.92 years were examined in the Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” and Kharkiv Railway Clinical Hospital No. 1 of the “Center of Healthcare” branch of Public Joint Stock Company “Ukrainian Railway”. The main group (group 1) included 74 patients with acute myocardial infarction and type 2 diabetes mellitus. The comparison group (group 2) was represented by 60 patients with acute myocardial infarction without type 2 diabetes mellitus. The control group was composed of 20 otherwise healthy individuals. Serum concentrations of insulin, adropin, irisin, fatty acid binding protein 4 and C1q/TNF-related protein were measured by enzyme-linked immunosorbent assays. Results and discussion. It was found that the levels of glucose, insulin, HOMA-IR index were increased in acute myocardial infarction patients with or without type 2 diabetes mellitus when compared with the control group (p˂0.05). In acute myocardial infarction patients with type 2 diabetes mellitus, the serum levels of adropin, irisin and C1q/TNF-related protein were significantly lower, while the fatty acid binding protein 4 levels were higher as compared to those in the control group (p<0.05). Acute myocardial infarction patients with type 2 diabetes mellitus demonstrated significantly lower serum concentrations of adropin and C1q/TNF-related protein in comparison with acute myocardial infarction patients without type 2 diabetes mellitus (p<0.05). Negative correlations between blood glucose and adropin (r = -0.499, p<0.001), irisin (r = -0.495, p<0.001), fatty acid binding protein 4 (r = -0.518, p<0.001), between HOMA-IR and adropin (r = -0.304, p<0.02), fatty acid binding protein 4 (r = -0.429, p = 0.001), as well as positive correlations between blood glucose levels and C1q/TNF-related protein (r = 0.435, p = 0.001) were revealed in acute myocardial infarction patients. In acute myocardial infarction patients with type 2 diabetes mellitus, negative correlations were found between blood glucose and adropin (r = -0.504, p<0.001), irisin (r = -0.520, p = 0.03), C1q/TNF-related protein (r = -0.546, p<0.001); between blood insulin and adropin (r = -0.361, p = 0.017), irisin (r = -0.396, p = 0.01), C1q/TNF-related protein (r = -0.361, p = 0.018); between adropin and HOMA-IR (r = -0.508, p = 0.001), C1q/TNF-related protein (r = -0.436, p = 0.003), as well as positive correlation between blood glucose and fatty acid binding protein 4 (r = 0.508, p = 0.007); between blood insulin and fatty acid binding protein 4 (r = 0.501, p = 0.001); between HOMA-IR and fatty acid binding protein 4 (r = 0.516, p<0.001). Conclusion. Characteristics of adropin, irisin, fatty acid binding protein 4 and C1q/TNF-related protein serum levels are evidence of violated energy and adipokine metabolism in both diabetic and non-diabetic patients with acute myocardial infarction. Relationships between adropin, irisin, fatty acid binding protein 4 and C1q/TNF-related protein could indicate involvement of these markers in carbohydrate metabolism

Keywords: adipokine, carbohydrate metabolism, acute myocardial infarction, energy homeostasis, type 2 diabetes mellitus

Full text: PDF (Eng) 254K

1. Khan M, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107-111. PMID: 32175717. PMCID: PMC7310804. https://doi.org/10.2991/jegh.k.191028.001
2. Cui J, Liu Y, Li Y, Xu F, Liu Y. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Front Cardiovasc Med. 2021;8:644189. PMID: 33718461. PMCID: PMC7943438. https://doi.org/10.3389/fcvm.2021.644189
3. Ramtahal R, Khan C, Maharaj-Khan K, Nallamothu S, Hinds A, Dhanoo A, et al. Prevalence of self-reported sleep duration and sleep habits in type 2 diabetes patients in South Trinidad. J Epidemiol Glob Health. 2015;5:S35-S43. PMID: 26073574. PMCID: PMC4666733. https://doi.org/10.1016/j.jegh.2015.05.003
4. Marenzi G, Cosentino N, Genovese S, Campodonico J, De Metrio M, Rondinelli M, et al. Reduced cardio-renal function accounts for most of the in-hospital morbidity and mortality risk among patients with type 2 diabetes undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Diab Care. 2019;42:1305-1311. PMID: 31048409. https://doi.org/10.2337/dc19-0047
5. Newsletter Top 10 causes of death in the world. WHO. December 9, 2020. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
6. Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CI, Goldberg RJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2018;17(1):136. https://doi.org/10.1186/s12933-018-0779-8
7. Jomaa W, El Mhamdi S, Ben Ali I, Azaiez MA, El Hraiech A, Ben Hamda K, et al. Prognostic value of hyperglycemia on-admission in diabetic versus non-diabetic patients presenting with ST-elevation myocardial infarction in Tunisia. Indian Heart J. 2018;70(6):772-776. https://doi.org/10.1016/j.ihj.2018.01.005
8. Li L, Xie W, Zheng XL, Yin WD, Tang CK. A novel peptide adropin in cardiovascular diseases. Clin Chim Acta. 2016;453:107-113. PMID: 26683354. https://doi.org/10.1016/j.cca.2015.12.010
9. Askin L, Uzel KE, Tanriverdi O, Turkmen S. Serum irisin: pathogenesis and clinical research in cardiovascular diseases. Cardiovasc Innov Appl. 2020;4(3):195-200. https://doi.org/10.15212/cvia.2019.0569
10. Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 (FABP4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol. 2015;8(3):23-33. PMID: 25674026. PMCID: PMC4315049. https://doi.org/10.4137/CMC.S17067
11. Yildirim A, Kucukosmanoglu M, Sumbul HE, Koc M. Reduced CTRP3 levels in patients with stable coronary artery disease and related with the presence of paroxysmal atrial fibrillation. Arq Bras Cardiol. 2022;118(1):52-58. PMID: 35195208. PMCID: PMC8959053. https://doi.org/10.36660/abc.20200669
12. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. PMID: 28886621. https://doi.org/10.1093/eurheartj/ehx393
13. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. PMID: 31497854. https://doi.org/10.1093/eurheartj/ehz486
14. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. PMID: 30288571. https://doi.org/10.1007/s00125-018-4729-5
15. Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J. 2018;65(7):685-691. PMID: 29669965. https://doi.org/10.1507/endocrj.EJ18-0060
16. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5):751-758. PMID: 24323892. https://doi.org/10.1515/cclm-2013-0844.
17. Yu HY, Zhao P, Wu MC, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014;190-191:46-49. PMID: 24731968. https://doi.org/10.1016/j.regpep.2014.04.001
18. Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J. Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis. J Diabetes. 2016;8(1):56-62. PMID: 25494632. https://doi.org/10.1111/1753-0407.12256
19. Xin C, Liu J, Zhang J, Zhu D, Wang H, Xiong L, et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond). 2016;40(3):443-451. PMID: 26403433. https://doi.org/10.1038/ijo.2015.199
20. Anastasilakis AD, Koulaxis D, Kefala N, Polyzos SA, Upadhyay J, Pagkalidou E, et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism. 2017;73:1-8. PMID: 28732565. https://doi.org/10.1016/j.metabol.2017.05.002
21. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30(10):2667-2672. PMID: 17620449. https://doi.org/10.2337/dc07-0413
22. Obokata M, Iso T, Ohyama Y, Sunaga H, Kawaguchi T, Matsui H, et al. Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2018;7(6):561-569. PMID: 30178960. https://doi.org/10.1177/2048872616683635
23. Qu H, Deng M, Wang H, Wei H, Liu F, Wu J, et al. Plasma CTRP-3 concentrations in Chinese patients with obesity and type II diabetes negatively correlate with insulin resistance. J Clin Lipidol. 2015;9(3):289-294. PMID: 26073386. https://doi.org/10.1016/j.jacl.2015.03.006
24. Yi W, Sun Y, Yuan Y, Lau WB, Zheng Q, Wang X, et al. C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation. 2012;125(25):3159-3169. PMID: 22653084. PMCID: PMC3391311. https://doi.org/10.1161/CIRCULATIONAHA.112.099937